Skip to main content
Log in

Are we Evaluating Correctly the Risk Accompanying Blood Pressure? The Case of White Coat and Masked Hypertension and Blood Pressure Variability

  • Invited Commentary
  • Published:
Current Cardiovascular Risk Reports Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31:1281–357.

    Article  PubMed  CAS  Google Scholar 

  2. Ruilope LM. Current challenges in the clinical management of hypertension. Nat Rev Cardiol. 2012;9:267–75.

    Article  CAS  Google Scholar 

  3. Rothwell PM. Limitations of the usual blood-pressure hypothesis and importance of variability, instability, and episodic hypertension. Lancet. 2010;375:938–48.

    Article  PubMed  Google Scholar 

  4. Mancia G, Bombelli M, Brambilla G, Facchtti G, Schwartz R, Sega R, et al. Long-term prognostic value of white coat hypertension: an insight from diagnostic use of both ambulatory and home blood pressure measurements. Hypertension. 2013;62:168–74.

    Article  PubMed  CAS  Google Scholar 

  5. Bulpitt CJ, Beckett N, Peters R, Staessen JA, Wang JG, Comsa M, et al. Does white coat hypertension require treatment over age 80? results of the hypertension in the very elderly trial ambulatory blood pressure side project. Hypertension. 2013;61:89–94.

    Article  PubMed  CAS  Google Scholar 

  6. Banegas JR, Segura J, Sobrino J, Rodriguez-Artalejo F, de la Sierra A, de la Cruz JJ, et al. Effectiveness of blood pressure control outside the clinical setting. Hypertension. 2007;49:62–8.

    Article  PubMed  CAS  Google Scholar 

  7. Hata J, Arima H, Rothwell PM, Woodward M, Zoungas S, Anderson C, et al. Effects of visit-to-visit variability in systolic blood pressure on macrovascular and microvascular complications in patients with type 2 diabetes: the ADVANCE trial. Circulation. 2013; [Epub ahead of print].

  8. Webb AJ, Rothwell PM. Effect of dose and combination of antihypertensives on interindividual blood pressure variability: a systematic review. Stroke. 2011;42:2860–5.

    Article  PubMed  CAS  Google Scholar 

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Luis M Ruilope has been a consultant for Novartis, Daiichi-Sankyo, Medtronic, BMS, and MSD, and has received payment for development of educational presentations from Medtronic. José R Banegas declares that he has no conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Luis M. Ruilope.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ruilope, L.M., Banegas, J.R. Are we Evaluating Correctly the Risk Accompanying Blood Pressure? The Case of White Coat and Masked Hypertension and Blood Pressure Variability. Curr Cardiovasc Risk Rep 7, 431–432 (2013). https://doi.org/10.1007/s12170-013-0360-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12170-013-0360-7

Keywords

Navigation